The Role of Relaxin-2 in Tissue Remodeling of Chronic Rhinosinusitis With Nasal Polyps

Abstract

Background

Relaxin is a small peptide hormone that regulates extracellular matrix remodeling and reduces fibrosis in a number of organs. Little is known about its impact on chronic rhinosinusitis with nasal polyps (CRSwNP); thus, we aimed to determine the expression of human H2 relaxin (relaxin-2) and its role in tissue remodeling in CRSwNP.

Methods

Patients were enrolled and divided into the following groups: CRS with NP (CRSwNP; n = 20), CRS without NP (CRSsNP; n = 20), and controls (n = 15). Tissue samples were analyzed by Masson trichrome staining for collagen, while the location and expression of relaxin-2, transforming growth factor beta 1 (TGF-β1), and phosphorylated (p) Smad2/Smad3 were analyzed by immunohistochemistry and Western blot. The expression of relaxin-2, Smad2, Smad3, and TGF-β1 mRNA was tested by quantitative polymerase chain reaction (qPCR). Ex vivo NP were treated with relaxin-2 (n = 15) or TGF-β1 (n = 15). Collagen type I (collagen I), relaxin-2, and TGF-β1 levels in the culture supernatants were examined by enzyme-linked immunosorbent assay, while pSmad2/Smad3 in culture pellets was analyzed by Western blot, and the expression of Smad2 and Smad3 mRNA was tested by qPCR.

Results

The collagen, relaxin-2, TGF-β1, and pSmad2/Smad3 protein expression levels were significantly decreased in the CRSwNP group compared with the CRSsNP group (P < .05). The expression of relaxin-2, Smad2, Smad3, and TGF-β1 mRNA in the CRSsNP group was significantly higher than in the CRSwNP and control groups (P < .05). Compared with the ex vivo controls, in CRSwNP, the levels of TGF-β1, collagen I, pSmad2/Smad3, Smad2, and Smad3 were markedly decreased after relaxin-2 treatment. However, relaxin-2, collagen I, pSmad2/Smad3, Smad2, and Smad3 were remarkably increased after TGF-β1 treatment.

Conclusions

The antifibrotic effects of relaxin-2 may play a role in tissue remodeling in CRSwNP, but the detailed mechanism deserves further study.

Keywords

chronic rhinosinusitis nasal polyps relaxin-2 transforming growth factor beta 1 tissue remodeling

Get full access to this article

View all access options for this article.

References

Akdis

Bachert

Cingi

, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2013; 131(6):1479–1490.

Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis of chronic rhinosinusitis: Inflammation. J Allergy Clin Immunol. 2011; 128(4):728–732.

Bachert C, Zhang N, van Zele T, Gevaert P. Chronic rhinosinusitis: from one disease to different phenotypes. Pediatr Allergy Immunol. 2012; 23(Suppl 22):2–4.

Yang YC, Zhang N, van Crombruggen K, Hu GH, Hong SL, Bachert C. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 2012; 67:1193–1202.

Shin JM, Um JY, Lee SA, Park IH , Lee SH, Lee HM. Effect of MeCP2 on TGF-β1-induced extracellular matrix production in nasal polyp-derived fibroblasts. Am J Rhinol Allergy. 2018; 32:228–235.

Van Bruaene

Van Crombruggen

, et al. Inflammation and remodelling patterns in early stage chronic rhinosinusitis. Clin Exp Allergy. 2012; 42(6):883–890.

Jiao

Wang

Duan

, et al. Transforming growth factor-beta1 decreases epithelial tight junction integrity in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2018; 141(3):1160.e9–1163.e9.

Massague

TGF-beta signal transduction.

Annu Rev Biochem. 1998; 67:753–791.

Van Bruaene

Derycke

Perez-Novo

, et al. TGF-beta signaling and collagen deposition in chronic rhinosinusitis. J Allergy Clin Immunol. 2009; 124(2): 253–259, 259.e1-2.

10.

Bachert

Zhang

Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'.

J Intern Med. 2012; 272(2):133–143.

11.

Bathgate

RAD

Hsueh

AJW

Sherwood

OD.

Physiology and molecular biology of the relaxin peptide family. In: Neill JD, ed. Knobil and Neill’s Physiology of Reproduction. New York, NY: Academic; 2006

12.

Sherwood

OD.

Relaxin's physiological roles and other diverse actions.

Endocr Rev. 2004; 25(2):205–234.

13.

Lin

, et al. Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action. Endocrinology. 2012; 153(8):3692–3700.

14.

Su W, Wang P, Chen H, Li H. Role of protein kinase C beta(2) in relaxin-mediated inhibition of cardiac fibrosis. J Endocrinol Invest. 2014; 37(6):559–564.

15.

Cernaro

Lacquaniti

Lupica

, et al. Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein. MedRes Rev. 2014; 34(1):77–105.

16.

Royce SG, Cheng V, Samuel CS, Tang ML. The regulation of fibrosis in airway remodeling in asthma. Mol Cell Endocrinol. 2012; 351(2):167–75.

17.

Samuel

Hewitson

TD.

Relaxin in cardiovascular and renal disease.

Kidney Int. 2006; 69(9):1498–1502.

18.

Fokkens

Lund

Mullol

, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012; 50(1):1–12.

19.

Pawankar R, Bunnag C, Khaltaev N, Bousquet J. Allergic rhinitis and its impact on asthma in Asia Pacific and the ARIA Update 2008. World Allergy Organ J. 2012; 5(Suppl 3):S212–S217.

20.

Derycke L, Zhang N, Holtappels G, Dutré T, Bachert C. IL-17A as a regulator of neutrophil survival in nasal polyp disease of patients with and without cystic fibrosis. J Cyst Fibros. 2012; 11(3):193–200.

21.

Yan

Zhao

, et al. Metoprolol inhibits cardiac apoptosis and fibrosis in a canine model of chronic obstructive sleep apnea. Cell Physiol Biochem. 2015; 36:1131–1141.

22.

Shi

Yang

Liu

, et al. Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. Br J Pharmacol. 2012; 165:1748–1756.

23.

Liu

Shen

Chen

Expression of androgen receptor in coronary artery in the cases of sudden coronary death. Int J Clin Exp Pathol. 2015; 8:3742–3747.

24.

Bathgate RA, Halls ML, Et VDW, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev. 2013; 93(1):405–480.

25.

Park

Chang

Hsu

SYT.

New Insights into Biological Roles of Relaxin and Relaxin-related Peptides.

Rev Endocr Metab Disord. 2005; 6(4):291–296.

26.

Bennett

RG.

Relaxin and its role in the development and treatment of fibrosis.

Transl Res. 2009; 154(1):1–6.

27.

Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol. 2010; 7(1):48–58.

28.

Mookerjee

Hewitson

Halls

, et al. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009; 23(4):1219–1229.

29.

Agoulnik

AI.

Relaxin and related peptides in male reproduction.

Adv Exp Med Biol. 2007; 612:49.

30.

Chen

Xiao

Liu

, et al. Differential expression of the aryl hydrocarbon receptor and transforming growth factor beta 1 in chronic rhinosinusitis with nasal polyps with allergic rhinitis. Orl J Otorhinolaryngol Relat Spec. 2017; 79(6):295–305.

31.

Takeda

Manabe

Cellular Interplay between cardiomyocytes and nonmyocytes in cardiac remodeling.

Int J Inflam. 2011; 2011(2):535241.

32.

Danielson

Conrad

KP.

Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats.

J Appl Physiol. 2003; 95(4):1509–1514.

33.

Samuel

Unemori

Mookerjee

, et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004; 145(9):4125–4133.

34.

Gajarsa

Kloner

RA.

Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities.

Heart Fail Rev. 2011; 16(1):13–21.

35.

Dschietzig T, Bartsch C, Baumann G, Stangl K. RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway. Regul Pept. 2009; 154(1):77–84.

36.

Becker

Hewitson

TD.

Relaxin and renal fibrosis.

Kidney Int. 2001; 59(3):1184–1185.

37.

Lekgabe

Kiriazis

Zhao

, et al. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension. 2005; 46(2):412–418.

38.

Meng

Qiao

, et al. Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis. J Allergy Clin Immunol. 2010; 125(5):1061–1068.

39.

Yang Y, Zhang N, Crombruggen KV, et al. Differential expression and release of activin A and follistatin in chronic rhinosinusitis with and without nasal polyps. PLoS One. 2015; 10(6):e0128564.

40.

Yang

Zhang

Lan

, et al. Transforming growth factor-beta 1 pathways in inflammatory airway diseases. Allergy. 2014; 69(6):699–707.

41.

Shin JM, Park JH, Kang B, Lee SA, Park IH, Lee HM. Effect of doxycycline on transforming growth factor-beta-1-induced matrix metalloproteinase 2 expression, migration, and collagen contraction in nasal polyp-derived fibroblasts. Am J Rhinol Allergy. 2016; 30:385–390.

42.

Heeg

MHJ

Koziolek

Vasko

, et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 2005; 68(1):96–109.

43.

Zhang

Van Zele

Perez-Novo

, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008; 122:961–996